+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

EyePoint Pharmaceuticals Inc (PSDV) - Product Pipeline Analysis, 2019 Update

  • PDF Icon

    Company Profile

  • 32 Pages
  • August 2019
  • GlobalData
  • ID: 4439692
Summary

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. EyePoint’s iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company EyePoint Pharmaceuticals Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

EyePoint Pharmaceuticals Inc Company Overview
  • EyePoint Pharmaceuticals Inc Company Snapshot
  • EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview
  • EyePoint Pharmaceuticals Inc – Pipeline Analysis Overview
  • EyePoint Pharmaceuticals Inc - Key Facts
  • EyePoint Pharmaceuticals Inc - Major Products and Services
  • EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage
  • EyePoint Pharmaceuticals Inc Pipeline Products Overview
  • Durasert - Front Of Eye Disease
  • Durasert - Front Of Eye Disease Product Overview
  • Durasert - Knee Osteoarthritis
  • Durasert - Knee Osteoarthritis Product Overview
  • Durasert Latanoprost Implant
  • Durasert Latanoprost Implant Product Overview
  • DURASERT With TKI - Wet AMD
  • DURASERT With TKI - Wet AMD Product Overview
  • Tethadur System
  • Tethadur System Product Overview
  • YUTIQ - Shorter Duration
  • YUTIQ - Shorter Duration Product Overview
  • EyePoint Pharmaceuticals Inc - Key Competitors
  • EyePoint Pharmaceuticals Inc - Key Employees
  • EyePoint Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Recent Developments
  • EyePoint Pharmaceuticals Inc, Recent Developments
  • Aug 07, 2019: EyePoint Pharmaceuticals reports second quarter 2019 financial results and highlights recent company progress
  • Jul 15, 2019: EyePoint Pharmaceuticals appoints Wendy DiCicco, CPA, to board of directors
  • Jun 10, 2019: EyePoint Pharmaceuticals strengthens executive leadership team with key hires
  • May 01, 2019: EyePoint Pharmaceuticals presents positive YUTIQ 36-month follow-up phase 3 data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  • Apr 16, 2019: EyePoint Pharmaceuticals to present at upcoming medical Conferences
  • Mar 14, 2019: Eyepoint Pharmaceuticals reports fiscal period ended december 31, 2018 financial results and highlights recent clinical and operational developments
  • Feb 13, 2019: EyePoint Pharmaceuticals secures up to $60 million debt facility
  • Feb 04, 2019: EyePoint Pharmaceuticals announces U.S. commercial launch of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg
  • Jan 28, 2019: EyePoint Pharmaceuticals names David Guyer, M.D., to Board of Directors
  • Nov 27, 2018: EyePoint Pharmaceuticals names Ron Honig, Esq., as SVP, general counsel & company secretary

Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer

List of Tables
  • EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview
  • EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type
  • EyePoint Pharmaceuticals Inc Pipeline Products by Indication
  • EyePoint Pharmaceuticals Inc, Key Facts
  • EyePoint Pharmaceuticals Inc, Major Products and Services
  • EyePoint Pharmaceuticals Inc Number of Pipeline Products by Development Stage
  • EyePoint Pharmaceuticals Inc Pipeline Products Summary by Development Stage
  • Durasert - Front Of Eye Disease - Product Status
  • Durasert - Front Of Eye Disease - Product Description
  • Durasert - Knee Osteoarthritis - Product Status
  • Durasert - Knee Osteoarthritis - Product Description
  • Durasert Latanoprost Implant - Product Status
  • Durasert Latanoprost Implant - Product Description
  • DURASERT With TKI - Wet AMD - Product Status
  • DURASERT With TKI - Wet AMD - Product Description
  • Tethadur System - Product Status
  • Tethadur System - Product Description
  • YUTIQ - Shorter Duration - Product Status
  • YUTIQ - Shorter Duration - Product Description
  • EyePoint Pharmaceuticals Inc, Key Employees
  • EyePoint Pharmaceuticals Inc, Subsidiaries
  • Glossary

List of Figures
  • EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type
  • EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Radius Health Inc
  • Eli Lilly and Co
  • Akers Biosciences Inc